The incidence of cervical cancer in low-and middle-income countries (LMICs) is five times higher than that observed in highincome countries (HICs). This discrepancy is largely attributed to the implementation of cytology-based screening programmes in HICs. However, due to reduced health system infrastructure requirements, HPV testing (self-and provider-collected) and visual inspection with acetic acid (VIA) have been proposed as alternatives that may be better suited to LMICs. Knowing the relative value of different screening options can inform policy and the development of sustainable prevention programs. We searched MEDLINE and EMBASE for English language publications detailing model-based cost-effectiveness analyses of cervical cancer screening methods in LMICs from 2000 to 2016. The main outcome of interest was the incremental costeffectiveness ratio (ICER). Quantitative data were extracted to compare commonly evaluated screening methods and a descriptive review was conducted for each included study. Of the initial 152 articles reviewed, 19 met inclusion criteria. Generally, cytology-based screening was shown to be the least effective and most costly screening method. Whether provider-collected HPV testing or VIA was the more efficient alternative depended on the cost of the HPV test, loss to follow-up and VIA test performance. Self-collected HPV testing was cost-effective when it yielded population coverage gains over other screening methods. We conclude that HPV testing and VIA are more cost-effective screening methods than cytology in LMICs. Policy makers should consider HPV testing with self-collection of samples if it yields gains in population coverage.
The incidence of cervical cancer in low-and middle-income countries (LMICs) is five times higher than that observed in highincome countries (HICs). This discrepancy is largely attributed to the implementation of cytology-based screening programmes in HICs. However, due to reduced health system infrastructure requirements, HPV testing (self-and provider-collected) and visual inspection with acetic acid (VIA) have been proposed as alternatives that may be better suited to LMICs. Knowing the relative value of different screening options can inform policy and the development of sustainable prevention programs. We searched MEDLINE and EMBASE for English language publications detailing model-based cost-effectiveness analyses of cervical cancer screening methods in LMICs from 2000 to 2016. The main outcome of interest was the incremental costeffectiveness ratio (ICER). Quantitative data were extracted to compare commonly evaluated screening methods and a descriptive review was conducted for each included study. Of the initial 152 articles reviewed, 19 met inclusion criteria. Generally, cytology-based screening was shown to be the least effective and most costly screening method. Whether provider-collected HPV testing or VIA was the more efficient alternative depended on the cost of the HPV test, loss to follow-up and VIA test performance. Self-collected HPV testing was cost-effective when it yielded population coverage gains over other screening methods. We conclude that HPV testing and VIA are more cost-effective screening methods than cytology in LMICs. Policy makers should consider HPV testing with self-collection of samples if it yields gains in population coverage.
Cervical cancer is a preventable disease due to its long natural history, the availability of screening tests to detect precancerous lesions and the efficacy of treatments for precancerous lesions. In addition, the recent introduction of prophylactic vaccines against human papillomavirus (HPV), the causal agent of cervical cancer, offers a new opportunity for prevention. In spite of this, there is a large burden of disease, experienced primarily by women in low-and middle-income countries (LMICs). Every year, 445,000 women in LMICs develop cervical cancer compared to 83,000 women in highincome countries (HICs) . 1 This disparity is largely attributed to the absence of organized screening programs in LMICs. Although HPV vaccination programs are being scaled up globally, implementation has been slow in LMICs. 2 The vaccine is targeted at adolescents before sexual debut and will not help women already infected with HPV. Therefore, screening programs will continue to be necessary for cervical cancer prevention. Screening alone may be a highly effective strategy for prevention with incremental cost-effectiveness ratios below the per capita gross domestic product (GDP) of LMICs per year of life saved (a metric traditionally used to indicate good value for money). 3, 4 However, while cytology-complex infrastructure requirements and quality assurance issues. Instead, the WHO recommends either human papillomavirus (HPV) testing or visual inspection with acetic acid (VIA) for screening programs. 7 To guide health policy recommendations for optimizing cervical cancer screening, a systematic approach to evaluating the cost-effectiveness of screening with cervical cytology, HPV testing, and VIA is essential. While we identified systematic reviews that focused on either cervical cancer screening in LMICs 8 or the cost-effectiveness of cervical cancer screening, [9] [10] [11] we were unable to identify any review focusing exclusively on cost-effectiveness in LMICs. To fill this gap, we conducted a systematic review to synthesize the evidence on model-based cost-effectiveness studies of cervical cancer screening methods in LMICs. The objectives for performing this review were to (i) provide policy makers in LMICs with an overview of the costeffectiveness of different screening methods to aid decisionmaking and (ii) identify gaps in the literature to inform future research.
Material and Methods

Search strategy and selection criteria
A systematic review of the literature was conducted through MEDLINE and EMBASE for relevant publications. The search strategy was formed using medical subject headings and keywords from four categories: cervical cancer, screening, cost-effectiveness and LMICs (Table 1) . For an article to be identified during the search, it had to have at least one keyword (title and/or abstract) or medical subject heading from each of the four categories. Any difference in search terms between the two databases is because of different databasespecific medical subject headings. This search was supplemented with expert consultation, reference scanning and hand searches. All searching was concluded on May 11, 2016. To be included in this review, articles were required to be model-based cost-effectiveness analyses of cervical cancer screening methods in LMICs published in English-language journals between 2000 and 2016. LMICs were defined per World Bank criteria. 12 For studies that included costeffectiveness analyses of vaccination in addition to screening, only those that evaluated the cost-effectiveness of at least one screening method, independent of any vaccine intervention, were included in this review and only results pertaining exclusively to screening are discussed here. Studies that evaluated screening in both LMICs and HICs were included but results from HICs are not discussed. Two reviewers (AM and HA) independently reviewed all abstracts identified in the search; relevant abstracts identified by either reviewer were subject to full-text review to determine eligibility.
Data analysis
The main outcome of interest for this study was the incremental cost-effectiveness ratio (ICER), which is defined as the additional cost of a strategy divided by the additional benefit of a strategy, as compared to the next best strategy. The ICER is expressed in terms of cost per year of life saved (YLS) or cost per disability-adjusted life year (DALY) averted. A screening strategy is considered to be "dominated" when it is more costly and less or equally effective as an alternative or has a higher cost-effectiveness ratio than more effective options. Nondominated strategies are considered "efficient." Due to anticipated variability in screening algorithms in different studies, quantitative data were only extracted for commonly evaluated screening strategies. A coding sheet was developed to capture data and included mathematical model type; the country of inquiry; funding source; base case parameter assumptions on test sensitivity, specificity, population coverage, loss to follow-up and direct medical costs per test; percent reduction in cervical cancer incidence; discounted life expectancy after screening; ICER compared to next best strategy; ICER compared to no screening and currency (and year) used for calculation. Data from studies that reported results from multiple countries were extracted as a range of values.
To avoid oversimplification with this data extraction approach, a descriptive summary written for all included studies detailing all screening methods evaluated and results from simultaneous cost-effectiveness analyses of multiple 
Results
Search results
The initial database search and supplementary search methods identified 173 articles. After duplicates were removed, 152 abstracts were reviewed by two reviewers which led to the identification of 45 potentially relevant articles (Cohen's k 5 0.806). All 45 articles were subject to full-text review and 19 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] met inclusion criteria ( Fig. 1) .
Study characteristics
As shown in Table 2 , 18 of the 19 included publications evaluated multiple screening methods in base case or sensitivity analyses. In all, 16 evaluated cytology, 16 evaluated providercollected HPV testing, 13 evaluated VIA and 7 evaluated selfcollected HPV testing. There was substantial variation between studies in assumptions regarding follow-up and treatment procedures, as well as with frequency and age of screening. The descriptive review in the Supporting Information outlines the various screening pathways evaluated by each study. The four most commonly described screening strategies were one-visit VIA (screening followed by immediate results and treatment if positive), two-visit self-collected HPV testing (screening 1 results and treatment if positive), two-visit provider-collected HPV testing (screening 1 results and treatment if positive) and three-visit cytology (screening 1 results and colposcopy/biopsy if positive 1 treatment), each performed once per lifetime at age 35. Quantitative data for these strategies are presented in Table 3 . When studies did not evaluate these screening strategies, results were still summarized in Table 3 for each included screening technology, but deviations from the most commonly evaluated screening pathways were noted. 13, 15, 18, [22] [23] [24] 27, 31 Other screening strategies evaluated but not included in Table 3 are: one-visit rapid HPV testing (screening followed by immediate results and treatment if positive) 14, 20, 29 ; three-visit self-and providercollected HPV testing (screening 1 return for results and referral to colposcopy if positive 1 colposcopy) 13, 15, 23, 25, 26 ; cotesting with two-visit VIA and HPV 15, 20, 21 ; two-visit VIA (colposcopy for screen-positive women) 26, 27 three-visit liquid-based cytology (LBC) 25 three-visit visual inspection with Lugol's iodine (VILI) 30 one-visit VIA at young ages followed by three-visit cytology screening at older ages 28, 29 and cotesting with three-visit cytology and providercollected HPV. 26 Of the 19 studies, 18 used either individual microsimulation models (11) or Markov models (7) to conduct their analyses; the remaining study used a decision tree model (Table 4) . 31 In several cases, the same models were used in multiple studies and were calibrated to the specific country being analyzed. In particular, seven studies 14 20 All models adopted a societal perspective, meaning that costs were included irrespective of the payer. For nearly all studies, discounting occurred at the WHO recommended rate of 3% 34 for future life years saved and costs; one study discounted at 3.6%, the interest rate used by the Bank of China. 30 The cost-effectiveness of screening was modeled in a wide variety of settings. Seven studies included countries in subSaharan Africa, 14, 16, 17, [19] [20] [21] 24 six included countries in Southeast Asia, 21, 22, 26, [29] [30] [31] five included countries in Latin America, 15, 16, 19, 21, 27 three included China, 19, 25, 30 three included India, 16, 18, 21 one included countries in the Middle East 23 and one included a country in Eurasia. 13 
Parameter assumptions
Baseline and average parameter assumptions are shown in Tables 3 and 5 , respectively, for one-visit VIA, two-visit selfcollected HPV testing, two-visit provider-collected HPV testing and three-visit cytology. Provider-collected HPV testing was assumed to be the most sensitive screening test with studies assuming an average sensitivity of 86%, followed by self-collected HPV testing, cytology and VIA. Cytology was assumed to be the most specific screening method at 92%; specific assumptions for other methods ranged from 82-87%. Population coverage assumptions were similar across screening methods and ranged from 69% to 74%. Average assumed loss to follow-up was highest with three-visit cytology (31%), followed by self-collected HPV testing (19%) and providercollected HPV testing (19%). As quantitative data were collected for one-visit VIA, there was no loss to follow-up. Average direct medical costs varied based on screening method, as shown in Table 5 .
Cost-effectiveness
For once in a lifetime screening, HPV testing strategies were found to be the most effective (Table 3 ). Nine of the eleven studies that compared either self-or provider-collected HPV For CIN21 unless otherwise indicated. 3 1 indicates expected gain in life expectancy compared to no screening. 4 Per year of life saved (YLS) unless otherwise indicated. 5 When the comparator is dominated, the ICER presented is relative to no screening or the next most effective nondominated screening method. 6 Sensitivity/specificity for HPV infection. 7 Due to multiregional analysis, data are only presented on AfricaD region for this article. 8 Positive screen leads to immediate colposcopy. Abbreviations: CS: cost saving; LTFU: loss to follow-up at any visit; p-HPV: provider-collected HPV testing; s-HPV: self-collected HPV testing.
testing once in a lifetime to VIA and/or cytology once in a lifetime found one of the HPV testing strategies to yield the greatest reduction in cervical cancer incidence. Provider-collected HPV testing was typically more effective than self-collected HPV testing, except in scenarios in which self-collection was assumed to increase population coverage. Cytology was consistently the least effective screening strategy.
Cytology was also dominated in cost-effectiveness analysis due to higher costs and lower or equivalent effectiveness by all other screening methods in all studies that evaluated multiple screening methods (Table 3 ). The efficiency of HPV testing versus VIA depended upon the relative costs and screening effectiveness; while HPV testing tended to be a more costly strategy and was sometimes dominated when VIA had high test sensitivity and fewer visits, HPV testing could also be a more efficient strategy (i.e., when VIA test sensitivity was poor or required a similar number of visits). ICERs of strategies that included multiple lifetime screens or combinations of different technologies followed the same trend as once in a lifetime screens. Provider-collected HPV testing was the most effective screening method in most studies. However, it did not always dominate VIA because of VIA's lower costs. Cytology-based programs were dominated in the majority of studies by HPV testing strategies and VIA. Self-collected HPV testing was only more cost-effective than provider-collected HPV testing when it was assumed to increase population coverage.
Discussion
The first objective of this review was to provide recommendations to policy-makers on the cost-effectiveness of different screening strategies. Results indicate that cytology is the least efficient screening method to implement in developing countries. Of the thirteen studies that evaluated cytology against other screening strategies in a simultaneous cost-effectiveness analysis, nine showed that it was dominated by HPV testing and/or VIA. Much of the difference in the cost-effectiveness of different strategies can be attributed to different parameter assumptions, as screening methods with higher assumed sensitivity and population coverage, but lower assumed loss to follow-up and screening costs, tended to be more costeffective. In this case, the sensitivity of cytology was estimated to be between 46 and 80%. This is substantially lower than the established sensitivity of HPV testing and in some articles may be an overestimation as a multicountry evaluation found cytology to have an average sensitivity of 58.4%. 6 Factors potentially contributing to this poor sensitivity in developing countries are inadequate facilities, limited quality assurance and a paucity of education resources for practitioners. 27 Additionally, the requirement of three visits to complete a full course of cytology screening leads to greater loss to follow-up compared to VIA and HPV testing, which can be conducted in one or two visits. In LMICs, the requirement of three visits to receive a full course of screening appears to represent a significant barrier to care. It thus behooves policy makers to implement screening efforts with as few visits as possible.
Comparing provider-collected HPV testing and VIA demonstrates that provider-collected HPV testing was generally more effective, yet also more costly than VIA. This is likely explained by the higher direct cost of HPV testing, as well as its greater sensitivity to detect precancerous conditions. The implication of this for policy makers is that the incremental cost of provider-collected HPV testing has to be weighed against the incremental gains in life years saved. Of the eleven studies showing provider-collected HPV testing to be the most effective screening method in individual countries (this does not include the one study demonstrating HPV to be most effective in a regional analysis 19 ), ten demonstrated providercollected HPV screening strategies that were nondominated and would reduce cervical cancer incidence at a cost less than the per capita GDP of at least one of the countries evaluated. This implies that HPV testing is often worth the extra investment over VIA. However, as results were not 100% consistent across studies, policy makers should still consider settingspecific trade-offs between sensitivity and loss to follow-up given the cost of provider-collected HPV. Campos et al. 17 provide an excellent framework to project incremental costs of different screening strategies given the anticipated variability of parameters in different settings. This is important because of concerns over the reliability of VIA resulting from the potential variability in test accuracy between providers. It has also been suggested that using community health workers may be a cost-effective way of reducing loss to follow-up for multiple visit strategies, such as HPV testing 35 ; however, this strategy was not evaluated in any of the reviewed articles.
Findings for HPV testing with self-collection of samples were not consistent. Seven studies were identified that evaluated cost-effectiveness of self-collection and among these, three 14, 20, 24 only evaluated self-collected HPV testing in sensitivity analyses where the assumed test accuracy of provider-collected HPV testing was reduced without changing assumptions on other parameter values. Under these assumptions, provider-collected HPV testing was more effective. However, this may not be an accurate reflection of actual parameter values for HPV testing with self-collection in a real world setting. A qualitative study in Uganda found that personal embarrassment was a significant barrier to screening, 36 which indicates that self-collection may increase population coverage. It is also plausible that costs would differ for self-collection due to reduced demands on practitioners. Under these different parameter assumptions, our results show that self-collected HPV testing is as or more efficient than provider-collected HPV testing. Ultimately, policy makers will have to take into account setting-specific factors when deciding on screening methods.
An area for future research is community-based self-collected HPV testing. This screening method entails community health workers making house visits to provide education and kits for self-collection. Despite an uptake rate of nearly 100% in a randomized trial in Uganda, 37 no cost-effectiveness study has yet evaluated this method of delivery. In addition to potentially increasing population coverage, community-based self-collection would likely be associated with different delivery and programmatic costs based on various pathways of care.
Several limitations of this research should be noted. Our ability to compare studies was limited because of variability in the type of screening methods analyzed, associated followup and treatment protocols and frequency and timing of screening. For instance, one study might evaluate VIA followed by immediate treatment with cryotherapy if screen positive once per lifetime at the age of 35, while a second might evaluate VIA followed by referral for colposcopy if screen positive every 5 years from the ages of 30 to 60. Additionally, in cost-effectiveness studies, the ICER is strongly influenced by the comparator and it can be difficult to capture variation in comparators between studies. As a result, we attempted to collect quantitative data on the once in a lifetime screen scenario and included the ICER comparator, when possible. In spite of this simplified data collection method, not all of the desired data were available.
We did not comment on methodological quality of individual studies. Therefore, limitations of individual studies may have influenced this systematic review. The costing data used by the included articles were often from microcosting studies and demonstration projects and thus may not reflect the actual cost of programs at a national scale. There was variability in model structure (Table 4) , with each model being subject to its own limitations. There were also several studies that employed the same models, as described in the results section. These studies all involved researchers from the Harvard Centre for Health Decision Science and account for every study that employed a microsimulation model. Consequently, individual studies are not necessarily independent from each other.
Implementing cervical cancer screening programs in developing countries is a moral imperative. In 2012, 230,000 women died in LMICs from cervical cancer 38 and most of these deaths are preventable. Every study reviewed in this article evaluated at least one screening strategy that reduced cervical cancer incidence at a cost per life saved below the studied country's GDP per capita, which demonstrates the economic feasibility of saving tens of thousands of lives per year. While more work needs to be done to evaluate emerging screening methods, every year that the status quo is maintained is another year that hundreds of thousands of women die from a preventable disease.
